Cargando…
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression
BACKGROUND: Metastatic melanoma has a high mortality rate and suboptimal therapeutic options. Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid × receptor selective agonist, and thiazolidinediones (TZD), PPARγ selective ligands, as novel treatments. RESULTS: Mouse xenograf...
Autores principales: | Klopper, Joshua P, Sharma, Vibha, Berenz, Andrew, Hays, William R, Loi, Michele, Pugazhenthi, Umarani, Said, Sherif, Haugen, Bryan R |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654861/ https://www.ncbi.nlm.nih.gov/pubmed/19267912 http://dx.doi.org/10.1186/1476-4598-8-16 |
Ejemplares similares
-
Combination PPARγ and RXR Agonist Treatment in Melanoma Cells: Functional Importance of S100A2
por: Klopper, Joshua P., et al.
Publicado: (2010) -
Self-Assembly Of Retinoid Nanoparticles For Melanoma Therapy
por: Liao, Han, et al.
Publicado: (2019) -
Chemotherapy and Chemoprevention by Thiazolidinediones
por: Fröhlich, Eleonore, et al.
Publicado: (2015) -
Thiazolidinediones and bone fractures
por: Kaku, Kohei, et al.
Publicado: (2011) -
Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention
por: Horita, Shoko, et al.
Publicado: (2015)